Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.

@article{Feng2014SynergisticIO,
  title={Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.},
  author={Qiang Feng and Min-Zhi Yu and Jian-Cheng Wang and Wen-jie Hou and Ling-Yan Gao and Xiao-fei Ma and Xi-Wei Pei and Yu-Jie Niu and Xiaoyan Liu and Chong Qiu and Wen-Hao Pang and Li-Li Du and Qiang Zhang},
  journal={Biomaterials},
  year={2014},
  volume={35 18},
  pages={5028-38}
}
A somatostatin analog, vapreotide (VAP), can be used as a ligand for targeting drug delivery based on its high affinity to somatostatin receptors (SSTRs), which is overexpressed in many tumor cells. RNA interference plays an important role on downregulation of vascular endothelial growth factor (VEGF), which is important for tumor growth, progression and metastasis. To improve tumor therapy efficacy, the vapreotide-modified core-shell type nanoparticles co-encapsulating VEGF targeted siRNA… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Tumor targeted delivery of siRNA by surface-modified LPC nanoparticles

  • T Yang, Zhao Z-X, Xu Z-Z, Zhao E-Y, Liu X-Y, Chen C-J
  • J Chin Pharm Sci 2011;7
  • 2011
1 Excerpt

Targeted delivery of RGDmodified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies

  • Zhang Y-f, Wang J-c, Bian D-y, X Zhang, Q Zhang
  • Eur J Pharm Biopharm 2010;74:467e73
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…